BIOMAT Database Logo BIOMAT Database Logo

Expression of urokinase-type plasminogen-activator (upa) and its receptor (upar) in human ovarian-cancer cells and in-vitro invasion capacity. 1994

C Will, and O Wilhelm, and S Hohl, and V Mobus, and U Weidle, and R Kreienberg, and F Janicke, and M Schmitt, and H Graeff
TECH UNIV MUNICH, KLINIKUM RECHTS ISAR, FRAUENKLIN, D-81675 MUNICH, GERMANY. UNIV ULM, FRAUENKLIN, D-89075 ULM, GERMANY. BOEHRINGER MANNHEIM GMBH, D-82377 PENZBERG, GERMANY.

Expression of urokinase-type plasminogen activator (uPA), tissue-type plasminogen activator (t-PA), their inhibitor PAI-1 and the uPA-receptor (uPAR) was characterized in six human tumor cell lines (OV-MZ-6, -10, -13, -15, -19 and OVCAR-3) established from patients with cystadenocarcinoma of the ovary. The invasive potential of the ovarian cancer cell lines determined in an in vitro invasion assay did neither correlate with the antigen level of uPA, t-PA, PAI-1 or uPAR nor with the cell surface uPA activity, however, did correlate with the cell surface-bound plasmin activity. The in vitro invasiveness of three cancer cell lines selected displaying a different pattern of uPA and uPAR expression was significantly inhibited by a recombinant soluble truncated form of the uPAR functioning as a scavenger for uPA. Our results suggest that the interference of the uPA/uPAR interaction leads to a reduced in vitro invasiveness of human ovarian cancer cells independent of the level of uPA and uPAR expression.

UI MeSH Term Description Entries

Related Publications

C Will, and O Wilhelm, and S Hohl, and V Mobus, and U Weidle, and R Kreienberg, and F Janicke, and M Schmitt, and H Graeff
Urokinase-type plasminogen activator (uPA) and its receptor (uPAR): development of antagonists of uPA/uPAR interaction and their effects in vitro and in vivo.
January 2003, Current pharmaceutical design,
C Will, and O Wilhelm, and S Hohl, and V Mobus, and U Weidle, and R Kreienberg, and F Janicke, and M Schmitt, and H Graeff
Urokinase-type plasminogen activator (uPA) and its receptor (uPAR) promote neurorepair in the ischemic brain.
January 2017, Receptors & clinical investigation,
C Will, and O Wilhelm, and S Hohl, and V Mobus, and U Weidle, and R Kreienberg, and F Janicke, and M Schmitt, and H Graeff
Amyloid beta-protein stimulates the expression of urokinase-type plasminogen activator (uPA) and its receptor (uPAR) in human cerebrovascular smooth muscle cells.
May 2003, The Journal of biological chemistry,
C Will, and O Wilhelm, and S Hohl, and V Mobus, and U Weidle, and R Kreienberg, and F Janicke, and M Schmitt, and H Graeff
Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor.
April 2006, International journal of oncology,
C Will, and O Wilhelm, and S Hohl, and V Mobus, and U Weidle, and R Kreienberg, and F Janicke, and M Schmitt, and H Graeff
Recombinant soluble urokinase receptor as a scavenger for urokinase-type plasminogen activator (uPA). Inhibition of proliferation and invasion of human ovarian cancer cells.
January 1994, FEBS letters,
C Will, and O Wilhelm, and S Hohl, and V Mobus, and U Weidle, and R Kreienberg, and F Janicke, and M Schmitt, and H Graeff
UVB increases urokinase-type plasminogen activator receptor (uPAR) expression.
July 1999, The Journal of investigative dermatology,
C Will, and O Wilhelm, and S Hohl, and V Mobus, and U Weidle, and R Kreienberg, and F Janicke, and M Schmitt, and H Graeff
Clinical significance of urokinase-type plasminogen activator receptor (uPAR) expression in cancer.
January 2004, Medicinal research reviews,
C Will, and O Wilhelm, and S Hohl, and V Mobus, and U Weidle, and R Kreienberg, and F Janicke, and M Schmitt, and H Graeff
Expression of urokinase-type plasminogen activator (uPA), its receptor (uPAR), and inhibitor (PAI-1) in human breast carcinomas and their clinical relevance.
February 2012, Journal of clinical laboratory analysis,
C Will, and O Wilhelm, and S Hohl, and V Mobus, and U Weidle, and R Kreienberg, and F Janicke, and M Schmitt, and H Graeff
Urokinase plasminogen activator (uPA) and its receptor (uPAR) in gestational tissues; Measurements and clinical implications.
May 2004, European journal of obstetrics, gynecology, and reproductive biology,
C Will, and O Wilhelm, and S Hohl, and V Mobus, and U Weidle, and R Kreienberg, and F Janicke, and M Schmitt, and H Graeff
Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors.
August 2017, Scientific reports,
Copied contents to your clipboard!